Summer Sale
50% off Premium Yearly
NYSE:JNJ
Johnson & Johnson (JNJ)
Financials 
Technical Analysis 
Aug 21, 2026, 12:00 amThis summary was created by AI, based on 10 opinions in the last 12 months.
Johnson & Johnson (JNJ) has shown some volatility recently, primarily due to performance issues in its cardio business, despite reporting a solid beat-and-raise quarter. The company has successfully addressed past legal challenges related to talcum powder, minimizing the overhang of these lawsuits. Analysts are optimistic about JNJ’s upcoming earnings report expected on July 15, anticipating positive news about its oncology drugs and orthopedic business, although caution persists due to erratic stock movements following disclosure of results. The spin-off of the orthopedics division is viewed positively as it shifts focus towards higher-margin pharmaceutical and medical device sectors. Overall, JNJ is seen as a solid investment due to its strong drug pipeline and improved balance sheet, even as the company navigates its litigation concerns.
'%20fill='%23ffffff'%3e%3cg%20id='Pager'%20transform='translate(423.000000,%201755.000000)'%3e%3cpath%20d='M243.295367,17.286474%20C243.68919,16.9045087%20244.327703,16.9045087%20244.721525,17.286474%20L249,21.4361302%20L253.278475,17.286474%20C253.672297,16.9045087%20254.31081,16.9045087%20254.704633,17.286474%20C255.098456,17.6684393%20255.098456,18.2877274%20254.704633,18.6696927%20L249.35654,23.856763%20C249.159628,24.0477457%20248.840372,24.0477457%20248.64346,23.856763%20L243.295367,18.6696927%20C242.901544,18.2877274%20242.901544,17.6684393%20243.295367,17.286474%20Z'%20id='Path'%20transform='translate(249.000000,%2020.500000)%20scale(-1,%201)%20rotate(-90.000000)%20translate(-249.000000,%20-20.500000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
